Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.55 |
| ▸ | HPGDS | O60760 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2709400 | 0.96 | PRCP (0.54) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL2707745 | 0.94 | PRCP (0.52) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL12965885 | 0.94 | PRCP (0.52) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL2710848 | 0.93 | CYP3A4 (0.54) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL2757500 | 0.93 | CYP3A4 (0.54) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL203107 | 0.93 | CYP3A4 (0.54) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL18582731 | 0.93 | PRCP (0.49) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL18582729 | 0.93 | PRCP (0.49) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL203503 | 0.91 | PRCP (0.50) | PRCPHPGDSNR1I2CYP3A4CYP2C9 | |
| SCHEMBL13070742 | 0.91 | HCRTR1 (0.52) | PRCPHPGDSNR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808325-A1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | Alla Chem, LLC. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074437-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | АЛЛА ХЕМ, ЛЛС (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | HCCS, EIF2AK2, HAVCR2 | PRCP 1773/4885HPGDS 1459/4885NR1I2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.